High-mobility group B1 (HMGBl) and receptor for advanced glycation end-products (RAGE) expression in canine lymphoma

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5043-5048

  Sterenczak, Katharina A ^a,b   Joetzke, Alexa E ^a   Willenbrock, Saskia ^a,b   Eberle, Nina ^a   Lange, Sandra ^c   Junghanss, Christian ^c   Nolte, Ingo ^a   Bullerdiek, Jörn ^a,b   Simon, Daniela ^a   Escobar, Hugo Murua ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Canine lymphoma; HMGB1; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BETA GLUCURONIDASE; HIGH MOBILITY GROUP B1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; COMPUTER PROGRAM; CONTROLLED STUDY; DOG; INTESTINE LYMPHOMA; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T CELL LYMPHOMA;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; LYMPHOMA; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78751545020     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Withrow S and Vail DM: Withrow and MacEwen's Small Animal Clinical Oncology, fourth edition. St. Louis: Saunders Elsevier, 2007.
2. Simon D, Moreno SN, Hirschberger J, Moritz A, Kohn B, Neumann S, Jurina K, Scharvogel S, Schwedes C and Reinacher M: Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. J Am Vet Med Assoc 232(6): 879-885, 2008.
3. Ono M, Torisu H, Fukushi J, Nishie A and Kuwano M: Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol 43(Suppl): 69-71,1999.
4. Moehler TM, Neben K, Ho AD and Goldschmidt H: Angiogenesis in hematologic malignancies. Ann Hematol 80(12): 695-705, 2001.
5. Andersson U, Erlandsson-Harris H, Yang H and Tracey KJ: HMGB1 as a DNA-binding cytokine. J Leukoc Biol 72(6): 1084-1091,2002.
6. Hussong JW, Rodgers GM and Shami PJ: Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95(1): 309-313, 2000. (Pubitemid 30017257)
7. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J and Palmblad J: Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 157(1): 15-19, 2000.
8. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G and Tefferi A: Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 96(10): 3374-3380, 2000.
9. Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, Vitelli G, Tucci L, Roccaro AM and Dammacco F: Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 100(9): 3344-3351, 2002.
10. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E and Folkman J: Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150(3): 815-821, 1997. (Pubitemid 27106153)
11. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G and Pezzella F: Angiogenesis in myelodysplastic syndromes. Br J Cancer 81(8): 1398-1401, 1999.
12. Ribatti D, Vacca A, Nico B, Fanelli M, Roneali L and Dammacco F: Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 56(1-2): 45-53, 1996. (Pubitemid 26075594)
13. Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A and Martinelli G: Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 106(2): 504-509, 1999.
14. Salven P, Teerenhovi L and Joensuu H: A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90(8): 3167-3172, 1997.
15. Salven P, Orpana A, Teerenhovi L and Joensuu H: Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96(12): 3712-3718, 2000.
16. Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S and Bullerdiek J: Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 166(4): 1259-1263, 2005.
17. van Beijnum JR, Buurman WA and Griffioen AW: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group Bl (HMGBl). Angiogenesis 11(1): 91-99,2008.
18. Sasahira T, Kirita T, Bhawal UK, Ikeda M, Nagasawa A, Yamamoto K and Kuniyasu H: The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 450(3): 287-295, 2007. (Pubitemid 46376559)
19. Wolfesberger B, Guija de Arespacohaga A, Willmann M, Gerner W, Miller I, Schwendenwein I, Kleiter M, Egerbacher M, Thalhammer JG, Muellauer L, Skalický M and Walter I: Expression of vascular endothelial growth factor and its receptors in canine lymphoma. J Comp Pathol 137(1): 30-40, 2007.
20. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ and Lotze MT: RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transi Med 7: 17, 2009.
21. Murua Escobar H, Meyer B, Richter A, Becker K, Flohr AM, Bullerdiek J and Nolte I: Molecular characterization of the canine HMGBl. Cytogen Genome Res 101: 33-38, 2003.
22. Murua Escobar H, Soller JT, Sterenczak KA, Sperveslage JD, Schlueter C, Burchardt B, Eberle N, Fork M, Nimzyk R, Winkler S, Nolte I and Bullerdiek J: Cloning and characterization of the canine receptor for advanced glycation end products. Gene 369: 45-52, 2006. (Pubitemid 43327330)
23. Sterenczak KA, Willenbrock S, Barann M, Klemke M, Soller JT, Eberle N, Nolte I, Bullerdiek J and Murua Escobar H: Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms. Gene 434(1-2): 35-42, 2009.
24. Owen LN: TNM Classification of Tumours in Domestic Animals. Geneva: World Health Organization, 1980.
25. Culmsee K, Simon D, Mischke R and Nolte I: Possibilities of flow cytometric analysis for immunophenotypic characterization of canine lymphoma. J Vet Med A Physiol Pathol Clin Med 48(4): 199-206, 2001.
26. Brinkhof B, Spee B, Rothuizen J and Penning LC: Development and evaluation of canine reference genes for accurate quantification of gene expression. Anal Biochem 356(1): 36-43, 2006.
27. Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30(9): e36, 2002.
28. Zizzo N, Patrono R, Zito FA, Di Summa A, Tinelli A, Troilo S, Misino A, Ruggieri E, Goffredo V, Gadaleta CD and Ranieri G: Vascular endothelial growth factor concentrations from platelets correlate with tumor angiogenesis and grading in a spontaneous canine non-Hodgkin lymphoma model. Leuk Lymphoma 51(2): 291-296,2010.
29. Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J, Wickenhauser C and Bullerdiek J: Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma 49(6): 1184-1189, 2008.
30. Meyer A, Eberle N, Bullerdiek J, Nolte I and Simon D: Highmobility group B1 proteins in canine lymphoma: prognostic value of initial and sequential serum levels in treatment outcome following combination chemotherapy. Vet Comp Oncol 8(2): 127-137,2010.
31. Hsieh HL, Schafer BW, Sasaki N and Heizmann CW: Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 307(2): 375-381, 2003.
32. Yu L and Chen S: Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother 57(9): 12711278,2008.
33. Nieters A, Beckmann L, Deeg E and Becker N: Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 7(8): 615-624, 2006. (Pubitemid 46242365)
34. Gough A: Breed Predispositions to Disease in Dogs and Cats. Oxford, Blackwell Publishing Ltd, 2004.